Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Q&As

Craig Bryan, PsyD, ABPP
Q&As
Implementing a Suicidal Ideation Crisis Response Plan
11/03/2021
In this Q&A, Craig Bryan, PsyD, ABPP, addressed some additional questions from his recent Psych Congress session, “Helping Your Patient Manage Suicidal Ideation and Behavior: Crisis Response Plan.”
In this Q&A, Craig Bryan, PsyD, ABPP, addressed some additional questions from his recent Psych Congress session, “Helping Your Patient Manage Suicidal Ideation and Behavior: Crisis Response Plan.”
In this Q&A, Craig Bryan, PsyD,...
11/03/2021
Psych Congress Network
Danielle J. Johnson, MD, FAPA
Q&As
COVID-19 Pandemic Increased Racial Disparities in Medical Care
11/01/2021
Danielle J. Johnson, MD, FAPA, answers questions about her session at the 2021 Psych Congress titled "Diversity and Cultural Competence: The Impact of “Dual Pandemics” on Women’s Mental Health".
Danielle J. Johnson, MD, FAPA, answers questions about her session at the 2021 Psych Congress titled "Diversity and Cultural Competence: The Impact of “Dual Pandemics” on Women’s Mental Health".
Danielle J. Johnson, MD, FAPA,...
11/01/2021
Psych Congress Network

Advertisement

Lasseter
Q&As
Premenstrual Dysphoric Disorder & Premenstrual Exacerbation: Diagnosis and Treatment
10/30/2021
Kristin Yeung Lasseter, MD presented a session titled “Mood Disorders Related to the Menstrual Cycle” at this weekend’s Psych Congress in San Antonio, Texas.
Kristin Yeung Lasseter, MD presented a session titled “Mood Disorders Related to the Menstrual Cycle” at this weekend’s Psych Congress in San Antonio, Texas.
Kristin Yeung Lasseter, MD...
10/30/2021
Psych Congress Network
Jay Fawver, MD Parkview Behavioral Health Institute
Q&As
Vortioxetine Significantly Reduces Symptom Severity in Patients With MDD
10/29/2021
Jay Fawver, MD, discusses a Psych Congress poster about vortioxetine significantly reducing depression severity in patients with MDD.
Jay Fawver, MD, discusses a Psych Congress poster about vortioxetine significantly reducing depression severity in patients with MDD.
Jay Fawver, MD, discusses a...
10/29/2021
Psych Congress Network
Niyati Butala
Q&As
Studying the Impact of Pharmacist-Driven Tardive Dyskinesia Screening
09/08/2021
In this Q&A session, Niyati Butala, Clinical Psychiatric Pharmacist, Riverside University Health System, Riverside, CA, discusses findings from the prospective quality improvement study “Impact of a pharmacist-driven tardive dyskinesia...
In this Q&A session, Niyati Butala, Clinical Psychiatric Pharmacist, Riverside University Health System, Riverside, CA, discusses findings from the prospective quality improvement study “Impact of a pharmacist-driven tardive dyskinesia...
In this Q&A session, Niyati...
09/08/2021
Psych Congress Network

Advertisement

kaftarian
Q&A
Structuring Telepsychiatry Group Therapy Sessions
07/30/2021
Edward Kaftarian, MD discusses group demographics and offers suggestions on the best ways to structure remote group therapy sessions.
Edward Kaftarian, MD discusses group demographics and offers suggestions on the best ways to structure remote group therapy sessions.
Edward Kaftarian, MD discusses...
07/30/2021
Psych Congress Network
Dr Kaftarian
Q&A
Group Therapy Sessions are on the Horizon for Telepsychiatry
07/16/2021
Psych Congress Steering Committee member Edward Kaftarian, MD, discusses the idea of group therapy for telepsychiatry.
Psych Congress Steering Committee member Edward Kaftarian, MD, discusses the idea of group therapy for telepsychiatry.
Psych Congress Steering...
07/16/2021
Psych Congress Network
Telehealth visit
Q&As
Highlighting the Strengths of Telemental Health Services for Patients and Clinicians
07/06/2021
In part two of this Q and A, researchers discuss their recent virtual APA session, including the strengths of telehealth services, practical implications for clinicians, and the future of telehealth.  
In part two of this Q and A, researchers discuss their recent virtual APA session, including the strengths of telehealth services, practical implications for clinicians, and the future of telehealth.  
In part two of this Q and A, ...
07/06/2021
Psych Congress Network

Advertisement

Chepke
Q&As
Takeaways From Updated Guideline Recommendations for Tardive Dyskinesia Treatment Using VMAT2 Inhibitors
06/30/2021
Craig Chepke, MD, FAPA discusses the key takeaways for clinicians from the updated guideline recommendations for treatment of tardive dyskinesia (TD) with vesicular monoamine transporter 2 (VMAT2) inhibitors.
Craig Chepke, MD, FAPA discusses the key takeaways for clinicians from the updated guideline recommendations for treatment of tardive dyskinesia (TD) with vesicular monoamine transporter 2 (VMAT2) inhibitors.
Craig Chepke, MD, FAPA discusses...
06/30/2021
Psych Congress Network
Dr Chepke
Q&As
Vigilant Screening for Tardive Dyskinesia Among Recommendations to Mitigate Symptom Severity
06/22/2021
Clinicians should be vigilant about screening patients for TD as earlier detection is key in improving or slowing illness severity, suggests Craig Chepke, MD, FAPA in this Q&A that expands on his Elevate session.
Clinicians should be vigilant about screening patients for TD as earlier detection is key in improving or slowing illness severity, suggests Craig Chepke, MD, FAPA in this Q&A that expands on his Elevate session.
Clinicians should be vigilant...
06/22/2021
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use